#Metformin er update
Extended-release metformin provides an appropriate option for patients with type 2 diabetes mellitus who require several medications to achieve glycemic control or manage comorbid conditions, and for those who have GI intolerance with the immediate-release formulation. Update FDA is alerting patients and health care professionals to two voluntary recalls of extended release (ER) metformin by Marksans Pharma and Sun. So far, brand name extended release metformin, Glucophage XR. Denne form for behandling anvendes fortrinsvis til overvægtige personer. Increased adherence may result in greater glycemic control, and in turn, improve outcomes and lower health care usage and costs. Metformin is a prescription drug used alone or with other drugs to treat Type 2 diabetes. XR (metformin hydrochloride) extended-release tablets, for oral use. Metformin 'Actavis' anvendes til behandling af: Diabetes type 2, hvor det forhøjede blodsukker ikke kan kontrolleres tilfredsstillende med diæt, vægttab og motion. The American Diabetes Association (ADA) recommends both metformin and metformin ER because they are both inexpensive and safe and because they’ve been shown to reduce the risk of diabetes complications for people who use them long term. Based on studies of extended-release formulations in other disease states, metformin extended-release formulation has the potential to improve patient adherence with a simpler dosing regimen and increased tolerability. Metformin and metformin ER are both approved to treat type 2 diabetes, alongside a healthy diet and exercise routine. Tolerability is generally comparable, although patients switched from the immediate-release formulation-even those switched due to GI intolerance-are often better able to tolerate the extended-release formulation. Extended-release metformin is as effective as immediate-release metformin in patients newly started on metformin and those switched from the immediate-release formulation, with similar weight-neutral effects. Maximum plasma metformin concentrations are reached more slowly with the extended-release formulation compared with conventional immediate-release metformin, although both provide similar exposure at a given total daily dose. Extended-release metformin improves GI tolerability, allows once-daily dosing, and is currently available in multiple branded and generic formulations however, it is more expensive than immediate-release metformin. In humans, independently of its action on glycaemia, immediate release metformin has favourable effects on lipid metabolism. Metformin is a first-line pharmacological treatment for patients with type 2 diabetes mellitus because of its favorable overall profile, including its glucose-lowering ability, weight-neutral effects, and low risk of hypoglycemia however, gastrointestinal (GI) intolerance may limit use in some patients.
0 kommentar(er)
